Education
About Us
Working with TipRanks
Follow Us
Esperion Therapeutics (GB:0IIM)
:0IIM
0IIM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.85 - $3.86
Previous CloseN/A
Volume10.92K
Average Volume (3M)40.95K
Market Cap
$182.30M
Enterprise Value$876.70M
Total Cash (Recent Filing)$20.89M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.01
Next Earnings
May 06, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding198,149,410
10 Day Avg. Volume16,945
30 Day Avg. Volume40,953
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.01
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market Cap4.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.64
Enterprise Value/Ebitda115.83
Forecast
1Y Price Target
$6.50Price Target Upside647.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Esperion News
PremiumCompany Announcements
Esperion Appoints Robert E. Hoffman as New Director
---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentEsperion Therapeutics has shown significant potential in its drug development pipeline.
Revenue GrowthEsperion's financials show a significant U.S. net product revenue growth of 52% year-over-year in 4Q24.
Strategic PartnershipsEsperion Therapeutics has made strategic partnerships that could enhance its growth opportunities.
Bears Say
Competitive LandscapeThere are concerns about the competitive landscape which may impact Esperion Therapeutics' market position.
Regulatory ChallengesChallenges in regulatory approvals could pose risks to Esperion Therapeutics' future prospects.
Sales PerformanceUS sales of bempedoic acid (BA) missed by -$3M (-8%), marking the 3rd consecutive quarter the franchise has come in below.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.75% Insiders
18.64%
Mutual Funds
27.45% Other Institutional Investors
42.41% Public Companies and
Individual Investors
0IIM FAQ
What was Esperion Therapeutics’s price range in the past 12 months?
Esperion Therapeutics lowest share price was $0.85 and its highest was $3.85 in the past 12 months.
What is Esperion Therapeutics’s market cap?
Esperion Therapeutics’s market cap is $182.30M.
When is Esperion Therapeutics’s upcoming earnings report date?
Esperion Therapeutics’s upcoming earnings report date is May 06, 2025 which is in 10 days.
How were Esperion Therapeutics’s earnings last quarter?
Esperion Therapeutics released its earnings results on Mar 04, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.149 by $0.039.
Is Esperion Therapeutics overvalued?
According to Wall Street analysts Esperion Therapeutics’s price is currently Undervalued.
Does Esperion Therapeutics pay dividends?
Esperion Therapeutics does not currently pay dividends.
What is Esperion Therapeutics’s EPS estimate?
Esperion Therapeutics’s EPS estimate is -0.16.
How many shares outstanding does Esperion Therapeutics have?
Esperion Therapeutics has 198,149,410 shares outstanding.
What happened to Esperion Therapeutics’s price movement after its last earnings report?
Esperion Therapeutics reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.149. Following the earnings report the stock price went up 12.258%.
Which hedge fund is a major shareholder of Esperion Therapeutics?
Currently, no hedge funds are holding shares in GB:0IIM
---
Esperion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (647.13% Upside)
$6.50 (647.13% Upside)
Blogger Sentiment
Bullish
GB:0IIM Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $29.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
67.81%
Trailing 12-Months
Company Description
Esperion Therapeutics
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
---
0IIM Company Deck
---
0IIM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements including FDA label expansions, strong revenue growth, and successful global partnerships. However, challenges such as the impact of the Medicare coverage gap and a slow start to 2025 prescription trends were also noted.Read More>---
0IIM Stock 12 Month Forecast
Average Price Target
$6.50
▲(647.13% Upside)
Technical Analysis
Emergent Biosolutions
―
Ironwood Pharma
―
Lifecore Biomedical
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Best Analysts Covering 0IIM
1 Year
1 Year Success Rate
8/24 ratings generated profit
1 Year Average Return
+18.29%
reiterated a buy rating 2 months ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +18.29% per trade.
---